tooluniverse-multiomic-disease-characterization

tooluniverse-multiomic-disease-characterization is a Bioinformatics & life sciences skill for AI agents, published by FreedomIntelligence in the OpenClaw-Medical-Skills repository on GitHub. Skillspace rates tooluniverse-multiomic-disease-characterization D (57/100) and it passed the safety scan; the rating is based on static analysis only.

Comprehensive multi-omics disease characterization integrating genomics, transcriptomics, proteomics, pathway, and therapeutic layers for systems-level understanding. Produces a detailed multi-omics report with quantitative confidence scoring (0-100), cross-layer gene concordance analysis, biomarker candidates, therapeutic opportunities, and mechanistic hypotheses. Uses 80+ ToolUniverse tools across 8 analysis layers. Use when users ask about disease mechanisms, multi-omics analysis, systems biology of disease, biomarker discovery, or therapeutic target identification from a disease perspective.

Grade
D
Quality
57 / 100
Safety
Passed
GitHub stars
2,848

Unproven: rated by static analysis only, not yet compared head-to-head.

Our two independent classifiers differ on this skill's category, so treat the placement as provisional.

This rating describes the version of the repository we crawled; it may have changed since, so go by its current files.

Our review

Architecture
76 / 100
Maturity
Structured: ships references or scripts
Security scan
Low-risk patterns
License
Not declared. Check the repository before reusing it.
Adoption
Adopted by 2 other repositories, in 13 collections

What the scanner flagged

  • mentions secrets in text

Not checked yet

  • Not judged on the rubric yet (not a contender in its category)
  • No blind task eval yet
  • Scope (portable / vendor / repo-internal) not assessed; only the top of each category is read for scope
  • Sibling files (scripts, references) not fetched; security scan covers SKILL.md only

Skillspace indexes and rates this skill; it does not host or endorse it. Run third-party skills at your own risk.